Innovation, Science and Economic Development Canada - advocating that the federal government work across all government relevant Ministries and with key stakeholders to advance the adoption of novel and innovative health innovations and grow the medical technology industry in Canada including forming a permanent cross ministerial and stakeholder collaborative roundtable/advisory group. Advocating for the development of a commercialization framework and adoption of medical technologies & health innovations strategy in Canada.Read more
Ritu Banerjee · Interim Head, Innovation, Science and Economic Development Canada (ISED)
Discussions re. Policies to incent global medical technology companies to invest their R&D dollars in Canada, changes to the Scientific Research and Experimental Development tax credit and the impact on medical technology companies in Canada, the adoption of a common national framework to measuring health outcomes resulting in greater efficiencies and lower costs.Read more
Lesley Sherban · Chief of Staff to the Minister, Global Affairs Canada (GAC)
Discussions re. Policies to incent global medical technology companies to invest their R&D dollars in Canada, changes to the Scientific Research and Experimental Development tax credit and the impact on medical technology companies in Canada, the adoption of a common national framework to measuring health outcomes resulting in greater efficiencies and lower costs.Read more
Bruce Randall · Director General, Health Canada (HC)
Medical Device Bureau: discussions re. a program that assesses safety, effectiveness and quality of medical devices with respect to the authorization for the sale of medical device technologies in Canada.Read more
Environmental regulation of Medical Devices (Canadian Environment Protection Act (CEPA), Chemicals Management Plan, provincial Stewardship regulations), Addressing issues and providing advice related to Medical Devices concerned by these regulations and participation in legislative/regulatory processes with the intent of seeking reasonable approaches based on scientific evidence and revising policies where needed.
Advancing the recommendations made by the Health & Biosciences Economic Strategy Table to grow the medical technology industry in Canada.
Jason Easton · Strategic Advisor Special Projects, Prime Minister's Office (PMO)
Stephanie Di Tripani · Director, Health Canada (HC)
Innovation, Science and Economic Development Canada - advocating that the federal government work across all government relevant Ministries and with key stakeholders to advance the adoption of novel and innovative health innovations and grow the medical technology industry in Canada including forming a permanent cross ministerial and stakeholder collaborative roundtable/advisory group. Advocating for the development of a commercialization framework and adoption of medical technologies & health innovations strategy in Canada.Read more
Discussions re. Policies to incent global medical technology companies to invest their R&D dollars in Canada, changes to the Scientific Research and Experimental Development tax credit and the impact on medical technology companies in Canada, the adoption of a common national framework to measuring health outcomes resulting in greater efficiencies and lower costs.
Mark Holland · Minister of Health, Health Canada (HC)
Innovation, Science and Economic Development Canada - advocating that the federal government work across all government relevant Ministries and with key stakeholders to advance the adoption of novel and innovative health innovations and grow the medical technology industry in Canada including forming a permanent cross ministerial and stakeholder collaborative roundtable/advisory group. Advocating for the development of a commercialization framework and adoption of medical technologies & health innovations strategy in Canada.Read more
Discussions re. Policies to incent global medical technology companies to invest their R&D dollars in Canada, changes to the Scientific Research and Experimental Development tax credit and the impact on medical technology companies in Canada, the adoption of a common national framework to measuring health outcomes resulting in greater efficiencies and lower costs.
Jonathan Alomoto · Senior Policy Advisor, Global Affairs Canada (GAC)
Innovation, Science and Economic Development Canada - advocating that the federal government work across all government relevant Ministries and with key stakeholders to advance the adoption of novel and innovative health innovations and grow the medical technology industry in Canada including forming a permanent cross ministerial and stakeholder collaborative roundtable/advisory group. Advocating for the development of a commercialization framework and adoption of medical technologies & health innovations strategy in Canada.Read more
Discussions re. Policies to incent global medical technology companies to invest their R&D dollars in Canada, changes to the Scientific Research and Experimental Development tax credit and the impact on medical technology companies in Canada, the adoption of a common national framework to measuring health outcomes resulting in greater efficiencies and lower costs.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence.
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.